Everhart Financial Group Inc. cut its stake in Danaher Co. (NYSE:DHR – Free Report) by 39.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,205 shares of the conglomerate’s stock after selling 1,450 shares during the period. Everhart Financial Group Inc.’s holdings in Danaher were worth $506,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the stock. Kovack Advisors Inc. boosted its position in shares of Danaher by 3.4% in the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after acquiring an additional 41 shares during the last quarter. Waypoint Capital Advisors LLC lifted its position in Danaher by 0.9% during the third quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock valued at $1,257,000 after buying an additional 42 shares in the last quarter. Gilbert & Cook Inc. lifted its position in Danaher by 2.5% during the fourth quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock valued at $401,000 after buying an additional 42 shares in the last quarter. Grimes & Company Inc. lifted its position in Danaher by 0.6% during the fourth quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock valued at $1,696,000 after buying an additional 43 shares in the last quarter. Finally, Harbour Investments Inc. lifted its position in Danaher by 3.0% during the third quarter. Harbour Investments Inc. now owns 1,531 shares of the conglomerate’s stock valued at $426,000 after buying an additional 45 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 11.10% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on Danaher
Danaher Stock Performance
Danaher stock opened at $206.66 on Monday. The company has a market cap of $149.26 billion, a PE ratio of 39.14, a P/E/G ratio of 2.68 and a beta of 0.83. The company has a fifty day moving average price of $229.53 and a two-hundred day moving average price of $249.33. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a 12 month low of $196.80 and a 12 month high of $281.70.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the prior year, the firm earned $2.09 earnings per share. Research analysts expect that Danaher Co. will post 7.67 earnings per share for the current year.
Danaher Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio is presently 20.45%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- 3 Tickers Leading a Meme Stock Revival
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- What Are Dividend Achievers? An Introduction
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.